{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:41:39Z","timestamp":1794004899005,"version":"4.8.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Boston Scientific Corporation","award":["no"],"award-info":[{"award-number":["no"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Conventionally fractionated radiotherapy is a common treatment for men with localized prostate cancer. A growing consensus suggests that stereotactic body radiation therapy (SBRT) is similarly effective but less costly and more convenient for patients. The SpaceOAR hydrogel rectal spacer placed between the prostate and rectum reduces radiation-induced rectal injury in patients receiving conventionally fractionated radiotherapy, but spacer efficacy with SBRT is unclear. The purpose of this research was to assess the clinical utility of the hydrogel rectal spacer in men receiving SBRT for prostate cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We performed systematic searches of Medline, Embase, and the Cochrane Central Register of Controlled Trials for studies in men who received the SpaceOAR hydrogel spacer prior to SBRT (\u22655.0\u200aGy fractions) for treatment of localized prostate center. Rectal irradiation results were compared to controls without spacer implant; all other outcomes were reported descriptively owing to lack of comparative data incuding perirectal separation distance, rectal irradiation on a dosimetric curve, gastrointestinal (GI) toxicity, and freedom from biochemical failure. GI toxicity was reported as the risk of a grade 2 or 3+ bowel complication in early (\u22643\u200amonths) and late (&gt;3\u200amonths) follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In 11 studies with 780 patients, SBRT protocols ranged from 7 to 10\u200aGy per fraction with total dose ranging from 19 to 45\u200aGy. Perirectal distance achieved with the rectal spacer ranged from 9.6 to 14.5\u200amm (median 10.8\u200amm). Compared to controls receiving no spacer, SpaceOAR placement reduced the radiation delivered to the rectum by 29% to 56% across a dosimetric profile curve. In early follow-up, grade 2 GI complications were reported in 7.0% of patients and no early grade 3+ GI complications were reported. In late follow-up, the corresponding rates were 2.3% for grade 2 and 0.3% for grade 3 GI toxicity. Over 16\u200amonths median follow-up, freedom from biochemical failure ranged from 96.4% to 100% (pooled mean 97.4%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>SpaceOAR hydrogel spacer placed between the prostate and rectum prior to SBRT is a promising preventative strategy that increases the distance between the prostate and rectum, reduces rectal radiation exposure, and may lower the risk of clinically important GI complications.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028111","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T13:10:42Z","timestamp":1639141842000},"page":"e28111","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":31,"title":["SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer"],"prefix":"10.1097","volume":"100","author":[{"given":"Heather A.","family":"Payne","sequence":"first","affiliation":[{"name":"Oncology Department, University College London Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pinkawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, MediClin Robert Janker Klinik, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Peedell","sequence":"additional","affiliation":[{"name":"James Cook University Hospital, Middlesbrough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir K.","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Health Economics and Market Access, Boston Scientific, Marlborough, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Woodward","sequence":"additional","affiliation":[{"name":"Boston Scientific AG, Ecublens, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1594-1885","authenticated-orcid":false,"given":"Larry E.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Miller Scientific, Johnson City, TN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"07","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pros.23496","article-title":"National trends in management of localized prostate cancer: a population based analysis 2004\u20132013","volume":"78","author":"Chen","year":"2018","journal-title":"Prostate"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1464-410X.2011.10554.x","article-title":"Open radical prostatectomy in the elderly: a case for concern?","volume":"109","author":"Trinh","year":"2012","journal-title":"BJU Int"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"JCO1801097","DOI":"10.1200\/JCO.18.01097","article-title":"Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline","volume":"36","author":"Morgan","year":"2018","journal-title":"J Clin Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ijrobp.2017.07.021","article-title":"Conventional versus hypofractionated radiation therapy for localized or locally advanced prostate cancer: a systematic review and meta-analysis along with therapeutic implications","volume":"99","author":"Datta","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijrobp.2014.06.044","article-title":"Optimization of radiation therapy techniques for prostate cancer with prostate-rectum spacers: a systematic review","volume":"90","author":"Mok","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"514","DOI":"10.21037\/qims.2018.06.06","article-title":"The role of radioprotective spacers in clinical practice: a review","volume":"8","author":"Tang","year":"2018","journal-title":"Quant Imaging Med Surg"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brachy.2019.08.009","article-title":"Optimization of prostate brachytherapy techniques with polyethylene glycol-based hydrogel spacers: a systematic review","volume":"19","author":"Afkhami Ardekani","year":"2019","journal-title":"Brachytherapy"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e208221","DOI":"10.1001\/jamanetworkopen.2020.8221","article-title":"Association of the placement of a perirectal hydrogel spacer with the clinical outcomes of men receiving radiotherapy for prostate cancer: a systematic review and meta-analysis","volume":"3","author":"Miller","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1748-717X-8-171","article-title":"Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study","volume":"8","author":"Alongi","year":"2013","journal-title":"Radiat Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2020.38.6_suppl.76","article-title":"Safety and outcome of stereotactic body radiation therapy (SBRT) with rectal hydrogel spacer for prostate cancer","volume":"38","author":"Chen","year":"2020","journal-title":"J Clin Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13014-020-01622-3","article-title":"Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5\u200aT MR-guided stereotactic body radiotherapy","volume":"15","author":"Cuccia","year":"2020","journal-title":"Radiat Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13014-019-1346-5","article-title":"Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes","volume":"14","author":"Hwang","year":"2019","journal-title":"Radiat Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13014-018-1135-6","article-title":"A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy","volume":"13","author":"Hwang","year":"2018","journal-title":"Radiat Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.meddos.2017.07.002","article-title":"Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials","volume":"42","author":"Jones","year":"2017","journal-title":"Med Dosim"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ijrobp.2017.09.020","article-title":"Multi-institutional phase 2 trial of high-dose stereotactic body radiation therapy with temporary hydrogel spacer for low- and intermediate-risk prostate cancer","volume":"99","author":"Folkert","year":"2017","journal-title":"Int Jo Radiat Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"20170672","DOI":"10.1259\/bjr.20170672","article-title":"Efficacy of a rectal spacer with prostate SABR-first UK experience","volume":"91","author":"King","year":"2018","journal-title":"Br J Radiol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"E298","DOI":"10.1016\/j.ijrobp.2019.06.1851","article-title":"A phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer; dosimetric comparison, acute toxicity and quality of life","volume":"105","author":"Ogita","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fonc.2019.00217","article-title":"Phase 2 multicenter study of gantry-based stereotactic radiotherapy boost for intermediate and high risk prostate cancer (PROMETHEUS)","volume":"9","author":"Pryor","year":"2019","journal-title":"Front Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jmrs.238","article-title":"Rectal protection in prostate stereotactic radiotherapy: a retrospective exploratory analysis of two rectal displacement devices","volume":"64","author":"Wilton","year":"2017","journal-title":"J Med Radiat Sci"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"20140736","DOI":"10.1259\/bjr.20140736","article-title":"Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer","volume":"88","author":"Ruggieri","year":"2015","journal-title":"Br J Radiol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jrr\/rraa013","article-title":"Comparison of rectal dose reduction by a hydrogel spacer among 3D conformal radiotherapy, volumetric-modulated arc therapy, helical tomotherapy, CyberKnife and proton therapy","volume":"61","author":"Saito","year":"2020","journal-title":"J Radiat Res"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.euo.2019.09.006","article-title":"Early tolerance and tumor control outcomes with high-dose ultrahypofractionated radiation therapy for prostate cancer","volume":"3","author":"Zelefsky","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"06","DOI":"10.1016\/S0360-3016(01)02664-5","article-title":"Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha\/beta ratio), similar to late-responding normal tissue","volume":"52","author":"Brenner","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R29-20250504","first-page":"583","article-title":"NCCN guidelines updates: management of prostate cancer","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.radonc.2020.04.037","article-title":"Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: a systematic review and meta-analysis of phase III randomized trials","volume":"148","author":"Lehrer","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:08:37Z","timestamp":1746335317000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028111"}},"subtitle":["A systematic review"],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":29,"journal-issue":{"issue":"49","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028111","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]},"assertion":[{"value":"2021-03-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}